The patient cohort (previously described in earlier studies on the PASD1 CTA [29, 30]) consisted of 22 patients with de novo DLBCL (two with relapsed DLBCL), seven patients with transformed DLBCL, and two patients with T cell rich B cell lymphoma.
CTL and CD4 Th Responses to Both the Sp17 and PASD1 CTAs.
We have previously reported, in the same cohort of patients, the presence of both CTL and CD4 Th responses to another CTA, the PASD1 protein [29, 30], which is also a member of the CT-X group.
It is interesting to note that the majority of the patients with detectable CTL and CD4 Th responses to Sp17 were previously reported to show significant T cell responses to another CTA, the PASD1 protein [29,30].
Collins et al., "Cytolytic T-cell response to the PASD1 cancer testis antigen in patients with diffuse large B-cell lymphoma," British Journal of Haematology, vol.